CTOs on the Move

Micell Technologies

www.micell.com

 
Micell Technologies Inc is a Raleigh, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.micell.com
  • 7516 Precision Dr
    Raleigh, NC USA 27617
  • Phone: 919.313.2102

Executives

Name Title Contact Details

Funding

Micell Technologies raised $25M on 11/18/2016

Similar Companies

Revolution Medicines

REVOLUTION Medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients. Our innovative product engine draws inspiration from nature and evolution, which offer insights into cancer targets, disease mechanisms and therapeutic approaches. We pay particular attention to natural products that are inherently rich with biological function as a result of natural selection and can inform and guide our discovery and development of small molecules that can modulate these targets.

Artemisia BioMedical

Artemisia BioMedical is a Renton, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cerecor

Cerecor is building a global biopharmaceutical enterprise with a near-term pipeline of six clinical programs. All of our pipeline products have unique and novel mechanisms of action with the potential to be first-in-class compounds.

Stratos Genomics

Stratos Group is dedicated to the conversion of science and technology into commercial solutions for the advancement of mankind and the protection of the environment. Also under the Stratos Group umbrella is Stratos Product Development. Stratos Product Development is a world leader in innovation and high tech product development services.

X-Vax Technology

We`re a biotech company committed to developing vaccines against pathogens acquired by mucosal infection such as herpes. Our research leads us to believe that the new approach we`re taking could succeed in defeating herpes by inducing antibodies that mediate the killing of infected cells. We`re strongly committed to this fight, and so far our work has been supported with unprecedented data in multiple preclinical models.